Journal article

Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3

Virginia Lay, Joanne Yap, Stefan Sonderegger, Evdokia Dimitriadis



Endometrial carcinoma is the most common gynaecological malignancy. There is however a lack of curative therapies, especially for patients diagnosed with late stage, recurrent or aggressive disease, who have a poor prognosis. Interleukin (IL) 11 is a pleiotropic cytokine that has a role in a number of cancers including colon and breast cancer. IL11 was recently found to be upregulated in endometrial cancers, however the function of IL11 in endometrial cancer is not known. This study aimed to determine the effects of IL11 on endometrial cancer cell proliferation, adhesion and migration. Three endometrial cancer cell lines, Ishikawa, HEC-1A and AN3CA (derived from endometrial cancers grade I, ..

View full abstract


Awarded by NHMRC of Australia

Funding Acknowledgements

We thank Dr Ellen Menkhorst for her contribution in editing the manuscript and technical advice. We thank Kirsten Edwards, Brent McKenzie, Andrew Nash and Pierre Scotney from CSL Biotherapies for provision of the IL11 antagonist. This study was funded by the NHMRC of Australia: ED is the funding recipient of Career Development Fellowship no. 550905 and V.L., J.Y. and S.S. are funded from project grant no. 388901. The study was also supported by the Victorian Government's Operational Infrastructure Support Program. PHI Data Audit 11-16.